Cefpodoxime Equivalent Dose for Augmentin 875-125 mg
Cefpodoxime 200 mg twice daily is the equivalent oral dose to Augmentin (amoxicillin-clavulanate) 875 mg/125 mg twice daily for adults with normal renal function.
Dosing Rationale
The equivalence is based on both guideline recommendations and FDA-approved dosing for similar infections:
Augmentin 875/125 mg twice daily is the standard adult dose for moderate to severe respiratory, ENT, skin, and genitourinary infections 1, 2
Cefpodoxime proxetil 200 mg twice daily provides comparable coverage and is the recommended dose for similar infection types 3, 4, 5
Clinical Context
This equivalence applies to:
- Respiratory tract infections (sinusitis, bronchitis, community-acquired pneumonia)
- ENT infections (otitis media, pharyngitis)
- Skin and soft tissue infections
- Uncomplicated urinary tract infections
Key Considerations
Spectrum differences to note:
- Cefpodoxime has enhanced activity against H. influenzae compared to amoxicillin alone 6
- Both agents provide good coverage for S. pneumoniae and S. aureus (methicillin-susceptible)
- Cefpodoxime is stable to most beta-lactamases but lacks activity against ESBL producers when used alone 6
When cefpodoxime may NOT be equivalent:
- ESBL-producing organisms: Recent research shows cefpodoxime alone is ineffective, though combinations with amoxicillin-clavulanate show synergy 7, 8
- Anaerobic coverage: Augmentin provides better anaerobic coverage due to clavulanate; cefpodoxime has limited anaerobic activity
- Enterococcal infections: Cefpodoxime lacks enterococcal coverage that amoxicillin provides
Practical Application
For acute bacterial sinusitis 9, 4:
- Cefpodoxime 200 mg twice daily for 5-10 days is guideline-recommended as equivalent to amoxicillin-clavulanate
For community-acquired pneumonia 5:
- Cefpodoxime 200 mg twice daily (with macrolide if comorbidities present) is an acceptable alternative to amoxicillin-clavulanate
For acute otitis media in children 9:
- Cefpodoxime proxetil 8 mg/kg/day divided twice daily is listed as equivalent to amoxicillin-clavulanate
Clinical Efficacy Data
Comparative trials demonstrate equivalent clinical and bacteriological cure rates between cefpodoxime 200 mg twice daily and amoxicillin-clavulanate 500/125 mg three times daily for respiratory infections 10, 11. The twice-daily dosing of cefpodoxime offers a compliance advantage over the three-times-daily standard Augmentin regimen 6.
Important caveat: If the patient is taking Augmentin 875/125 mg specifically for suspected ESBL producers or anaerobic infections, cefpodoxime alone is NOT an appropriate substitute. The clavulanate component is critical in these scenarios.